Axa
ANIK icon

Axa’s Anika Therapeutics ANIK Stock Holding History

Axa’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-19,200
Closed -$634K – 1444
2015
Q2 		$634K Sell
19,200
-2,700
-12% -$96.3K ﹤0.01% 1037
2015
Q1 		$902K Buy
21,900
+2,200
+11% +$88.9K ﹤0.01% 977
2014
Q4 		$803K Buy
19,700
+12,500
+174% +$489K ﹤0.01% 1012
2014
Q3 		$264K Buy
+7,200
New +$311K ﹤0.01% 1196
2014
Q2 		– Sell
-3,600
Closed -$148K – 1384
2014
Q1 		$148K Sell
3,600
-9,100
-72% -$338K ﹤0.01% 1251
2013
Q4 		$485K Sell
12,700
-23,300
-65% -$719K ﹤0.01% 1071
2013
Q3 		$863K Buy
36,000
+100
+0.3% +$2.25K ﹤0.01% 898
2013
Q2 		$610K Buy
+35,900
New +$518K ﹤0.01% 932

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

Axa's ANIK Position: Q3 2015 in Review

Axa sold out of Anika Therapeutics (ANIK) in Q3 2015, closing a stake of 19,200 shares — an estimated $634K sold.

Axa first reported a position in ANIK in Q2 2013 and held it in 8 quarters. The position peaked at $902K in Q1 2015. 138 funds tracked by Wall St. Rank hold ANIK as of Q3 2015.

  • Axa reported no remaining Anika Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Axa sold 19,200 Anika Therapeutics shares in Q3 2015, an estimated $634K.
  • Axa first reported a position in Anika Therapeutics in Q2 2013 and held it in 8 quarters.
  • Axa's Anika Therapeutics position peaked at $902K in Q1 2015.
  • 138 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2015.

Based on Axa's 13F filing for Q3 2015, filed 13 Nov 2015.